Previous studies reported that EGFR-TKI resistance is associated with YAP overexpression or YAP amplification, and silencing YAP by siRNA can reverse EGFR-TKI resistance in NSCLC cells [40, 118]. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.